Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Yearbook of Pediatrics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0084-3954(08)70095-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

  2005cited by this paper
• Effectiveness of Walking Exercise as a Bowel Preparation for Colonoscopy: A Randomized Controlled Trial

  2005cited by this paper

• The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long‐term clinical outcomes in patients with ulcerative colitis

  2023cites this paper
• Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease

  2023cites this paper
• Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders

  2021cites this paper
• Integrin-directed antibody-based immunotherapy: focus on VLA-4

  2021cites this paper
• Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data

  2021cites this paper
• Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis.

  2020cites this paper
• Histological scores in inflammatory bowel disease

  2020influential citation
• Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis

  2020cites this paper
• UEG Week 2020 Oral Presentations

  2020cites this paper
• Emerging treatments for inflammatory bowel disease

  2020cites this paper
• Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy

  2020influential citation
• On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis

  2020influential citation
• CE_A_179053 7..20

  2020influential citation
• A Global Survey of Gastroenterologists’ Travel Advice to Patients with Inflammatory Bowel Disease on Immunosuppressive Agents and Management of Those Visiting Tuberculosis-Endemic Areas

  2018cites this paper
• Estudi transcripcional de la Colitis Ulcerosa. Caracterització i cerca de biomarcadors

  2018cites this paper
• Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

  2017cites this paper
• Histologic Features with Predictive Value for Outcome of Patients with Ulcerative Colitis

  2017cites this paper
• Current best practice for disease activity assessment in IBD

  2016cites this paper
• Vedolizumab for the treatment of ulcerative colitis

  2016cites this paper
• Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

  2015cites this paper
• Gasotransmitters in cancer: from pathophysiology to experimental therapy

  2015cites this paper
• Multifunctional Activity of a Small Tellurium Redox Immunomodulator Compound, AS101, on Dextran Sodium Sulfate-induced Murine Colitis*

  2014cites this paper
• Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease

  2014cites this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cites this paper
• Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis

  2014cites this paper
• Vedolizumab as induction and maintenance therapy for Crohn's disease.

  2013cites this paper
• Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update

  2013cites this paper
• Novel treatment options for ulcerative colitis.

  2013cites this paper
• Tissue Specific Heterogeneity in Effector Immune Cell Response

  2013cites this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cites this paper
• Mechanics of the contact interface between cells and functionalized surfaces

  2013cites this paper
• Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases

  2012cites this paper
• Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease

  2012cites this paper
• A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

  2012cites this paper
• Structural specializations of α4β7, an integrin that mediates rolling adhesion

  2012cites this paper
• Structural specializations of \(\alpha_4 \beta_7\), an integrin that mediates rolling adhesion

  2012cites this paper
• Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases

  2012cites this paper
• Shining a Light on Intestinal Traffic

  2011cites this paper
• Future therapeutic approaches for inflammatory bowel diseases.

  2011cites this paper
• Ulcerative colitis.

  2011cites this paper
• Regional and mucosal memory T cells

  2011cites this paper
• Integrins as therapeutic targets: lessons and opportunities

  2010cites this paper
• Technical Advance: Function and efficacy of an α4‐integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis

  2010cites this paper
• Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights.

  2010cites this paper
• T-cell-directed therapies in inflammatory bowel diseases.

  2010cites this paper
• CCR9 and inflammatory bowel disease

  2009cites this paper
• Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there.

  2009cites this paper
• α4β7/MAdCAM-1 Interactions Play an Essential Role in Transitioning Cryptopatches into Isolated Lymphoid Follicles and a Nonessential Role in Cryptopatch Formation1

  2008cites this paper
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

  2008influential citation
• Novel therapeutic targets in the treatment of IBD

  2008influential citation
• Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies

  2007cites this paper
• Immunogenicity screening in protein drug development

  2007cites this paper
• Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation

  2007cites this paper
• Current and future therapies for inflammatory bowel disease

  2007cites this paper
• Natalizumab: a promising treatment for Crohn’s disease

  2006cites this paper
• Neutrophils and immunity: challenges and opportunities

  2006cites this paper
• Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis

  2006cites this paper
• Designer drugs: the biologic therapies.

  2006cites this paper
• Role of CCL25/CCR9 in immune homeostasis and disease

  2006cites this paper
• Integrin antagonists as therapeutics for inflammatory diseases

  2006influential citation
• From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease

  2006influential citation
• Tissue-tropic effector T cells: generation and targeting opportunities

  2006cites this paper
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

  2006cites this paper
• Bislang kein wirklicher Durchbruch - Biologika bei chronisch entzündlichen Darmerkrankungen

  2006cites this paper
• ICAM‐1‐dependent pathways regulate colonic eosinophilic inflammation

  2006cites this paper
• Evolving knowledge and therapy of inflammatory bowel disease

  2006cites this paper
• Immune cell migration in inflammation: present and future therapeutic targets

  2005cites this paper
• Clinical and Experimental Gastroenterology Dovepress

  year unknowncites this paper
• Biologics: Targets and Therapy Dovepress Selective Biologics for Ulcerative Colitis and Crohn's Disease – Clinical Utility of Vedolizumab

  year unknowncites this paper